Experimental Neurology

Traumatic brain injury (TBI) is one of the leading causes of emergency room visits in children under 10. Children are potentially more vulnerable to the adverse effects of TBI, given that their brains are still developing at the time of injury. Indeed, early life TBI has been linked to cognitive, social, and mood-related impairments later in life. The neuroimmune system has been implicated in adult TBI mechanisms and plays numerous key roles in brain development, making it an interesting candidate for linking pediatric TBI and prolonged behavioral alterations. Here we establish a rat model of mild pediatric TBI to investigate the relationship between early life TBI, acute responses of neuroimmune cells, and chronic behavioral dysregulation. At postnatal day 15, which is roughly equivalent to toddler age, male and female rat pups received a TBI via lateral fluid percussion injury. At 3 days post injury, TBI increased microglia and astrocyte coverage locally in the Perilesional Cortex but not in more distant corticolimbic regions. However, the hippocampus and prefrontal cortex did exhibit increased expression of the phagocytic marker CD68 in microglia, suggesting widespread glial activation even in the absence of gross coverage change. TBI also impacted mast cells, early-response innate immune cells, increasing their number and degranulation in multiple regions. In the juvenile and early adult periods, TBI impaired cognitive function, reduced sociability, and increased avoidance, with no change in anxiety-like behavior. Later in adulthood, TBI continued to impact cognitive behavior, increasing risky decision-making and impairing optimization months after injury. Together, these results suggest that pediatric TBI causes lasting cognitive and social dysregulation, possibly via acute neuroimmune alterations following injury at a critical period of brain development.

Dementia is a progressive condition that impairs cognitive processes such as memory, decision making, and the ability to manage daily activities. Recent estimates suggest that more than half of all dementia cases could be preventable by addressing their risk factors, including disease comorbidities such as diabetes and vision loss. Yet, we lack a comprehensive molecular map of dementia comorbidities. In this work, we analyzed Austrian nationwide hospital claims data, comprising 13 million hospital stays from 2015 to 2019, to systematically assess dementia-related risk across disease comorbidity patterns, covering both their molecular relationships and their epidemiological overrepresentation. We identified disease trajectories occurring before and at the time of dementia diagnosis, revealing both sex-specific and shared comorbidity patterns. Overall, we identified 51 potential risk factors, with a prominent contribution from endocrine and metabolic disorders. While Parkinson's disease emerged as a strong molecularly related driver of dementia, we also identified emerging and previously under chracterized risk factors, including vitamin D deficiency. This integrative framework provides a comprehensive view of dementia associated disease networks and identifies novel, potentially modifiable risk factors. These results offer new opportunities for targeted prevention strategies and advance our understanding of the complex interplay between comorbidities and dementia development.

Background: Cerebral vasospasm is a frequent complication after aneurysmal subarachnoid hemorrhage (aSAH) and is associated with delayed cerebral ischemia (DCI) and unfavorable outcome. While CTA-based vasospasm grading is frequently used, its relationship with actual cerebral perfusion remains incompletely understood. This study investigates the association between vasospasm severity and distribution and territorial perfusion deficits. Methods: In this retrospective single-center study, 513 CT examinations (CTA and CT perfusion) from 194 patients with aSAH were analyzed. Vasospasm was graded per vessel segment using the CTA Vasospasm Score, and perfusion deficits were assigned to corresponding vascular territories (left/right anterior circulation, posterior circulation). Vasospasm distribution was further classified by severity and multifocality. Associations between vasospasm score and perfusion deficits were assessed using a generalized linear mixed model with binomial distribution, adjusting for Hunt & Hess grade, modified Fisher score, and days since hemorrhage. Results: Vasospasm was detected in 79.3% of examinations, and a perfusion deficit in at least one territory was present in 62.6%. The proportion of perfusion deficits increased progressively with both vasospasm severity and multifocality, ranging from 21.7-25.0% in the absence of vasospasm to 81.2-82.2% in severe multifocal vasospasm. The CTA Vasospasm Score was significantly associated with perfusion deficits in all territories (OR 1.36-1.50), with stronger associations in the anterior than posterior circulation. Conclusion: Vasospasm severity and distribution are strongly associated with perfusion deficits, supporting a continuum model of ischemic risk. However, the substantial proportion of perfusion deficits occurring independent of vasospasm suggests additional microcirculatory mechanisms not captured by CTA. CT perfusion should be considered complementary to CTA, particularly in clinically deteriorating or non-assessable patients.

Importance: Neuroinflammation is a key component of the response to injury after concussion, but direct links between diffusion MRI metrics and specific plasma inflammatory pathways in human concussion have not been established. Objective: To examine associations between diffusion MRI metrics and pathway-level inflammatory proteomic signatures in adolescents during the subacute period after concussion. Design, Setting, and Participants: Cross-sectional analysis of data from the CARE4Kids Consortium, a six-site prospective study. Participants were English-speaking adolescents ages 11-17.99 with concussion and symptoms at 7-35 days post-injury. Data were collected between 2022-2024. Of 370 enrolled participants, 122 had both diffusion MRI and plasma proteomics available for analysis. Exposure: Advanced diffusion MRI metrics were converted to z-scores and participants were grouped by the spatial extent of outlier values (potholes and peaks) across 15 white matter regions of interest. Nine non-redundant groupings were selected for primary analysis. Main Outcomes and Measures: Pathway-level inflammatory profiles derived from gene set enrichment analysis (GSEA) of ~5,400 plasma proteins measured by Olink proximity extension assay, targeting nine hallmark inflammatory pathways spanning initiation through resolution. Persistent symptoms were assessed 64-115 days post-injury. Results: Diffusion metrics reflecting tissue disorganization were associated with upregulation of the coagulation pathway, consistent with hemostatic-inflammatory signaling. Metrics reflecting reduced tissue complexity and neurite density were associated with upregulation of interferon- and interferon-{gamma} response pathways, consistent with microstructural remodeling driven by cellular immune activation. Elevated free water content was associated with downregulation of most inflammatory pathways and trend-level transforming growth factor - {beta} upregulation, reflecting inflammatory resolution. Time since injury did not differ between groups based on free water (Kolmogorov-Smirnov p = 0.97), suggesting these differences reflect individual variability in recovery pace. Exploratory analyses showed a trend toward lower odds of persistent symptoms in the group with elevated free water content (odds ratio = 0.51, p = 0.18). Conclusions and Relevance: Multiple diffusion MRI metrics are differentially sensitive to distinct neuroinflammatory states in the subacute period after adolescent concussion. These findings suggest that diffusion imaging could serve as a non-invasive tool for inflammatory phenotyping, with potential implications for identifying patients who may benefit from targeted immunomodulatory intervention.

Magnetic Resonance Imaging (MRI) derived brain age varies substantially between individuals, but it remains unclear whether early deviations from normal brain ageing precede future cognitive decline and whether they provide predictive value beyond conventional MRI measures. Here, we investigated whether MRI-derived brain age gap estimation (BrainAGE) identifies early structural brain ageing differences among cognitively normal individuals who later develop mild cognitive impairment (MCI) or dementia. We analysed longitudinal structural MRI data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) and replicated the main findings in the population-based Kuopio Osteoporosis Risk Factor and Prevention Study (OSTPRE). Individuals who later converted to MCI or dementia had higher BrainAGE values several years before diagnosis and, in ADNI, showed steeper longitudinal increases than stable individuals. Elevated BrainAGE values were also associated with increased risk of future conversion to MCI in cognitively healthy individuals and faster subsequent memory decline. Cross-sectional differences and the association between BrainAGE and risk of future conversion were replicated in OSTPRE. Importantly, adding BrainAGE to models including demographic, APOE4, cognitive, and MRI-derived measures consistently improved prediction of future cognitive outcomes, with the greatest benefit observed for individuals who converted after longer follow-up. These findings show that structural brain ageing begins to diverge years before the onset of MCI. BrainAGE captures this early divergence, providing complementary information beyond conventional structural MRI measures that may improve the early identification of cognitively normal individuals at increased risk of future cognitive decline when integrated with other biomarkers.

Background: In Japan, health planning is organized around secondary medical areas (SMAs; niji-iryo-ken; 330 areas in the 2025 classification), yet nationwide analyses of intensive care unit (ICU) capacity have been conducted mainly at the prefecture level, and a recent SMA-level study addressed only the presence or absence of ICUs. The full supply structure of intensive and intermediate critical care - ICU and high care unit (HCU) beds - has not been characterized at the SMA level with respect to its composition, road-network accessibility, and evolution over time. Methods: We developed MeshScope-Region, an analytical platform built on the Hospital Bed Function Reports (byosho-kino-hokoku) for fiscal years 2016-2024, in which ICU and HCU beds were identified from notified reimbursement categories and aggregated to SMAs. Three analytical layers were integrated: (1) cross-sectional distribution of ICU/HCU beds; (2) nationwide road-network accessibility computed with the Open Source Routing Machine (OSRM) from 176,962 populated 1-km census grid cells to all facilities reporting ICU or HCU beds; and (3) a nine-year longitudinal analysis of supply-structure types, classified by k-means (k = 6) in an 8-dimensional PCA space anchored to fiscal year 2024, with earlier years projected into the same space. Results: In fiscal year 2024, 20,631 ICU/HCU beds were reported nationally (7,114 ICU-type; 13,517 HCU-type) at 1,044 facilities. Zone-level totals among SMAs with any beds ranged 229-fold (3-688 beds); the 90th/10th percentile ratio of per-capita density was 3.6. In total, 90.1% of the population resided within 30 minutes' drive of a facility with ICU beds and 97.8% within 60 minutes; only 0.8% resided beyond 90 minutes. Although 140 of the 330 SMAs had no ICU facility within their own boundaries, 84.7% of their residents could reach an ICU facility in an adjacent area within 60 minutes' drive. Longitudinally, supply structures were highly persistent: 63.0% of SMAs (208/330) retained the same structural type across all nine years, adjacent-year rank correlations of a supply-vulnerability index were 0.887-0.924 (2016 vs. 2024: rho = 0.711), and the number of SMAs with zero ICU beds remained frozen at 133-141. The Gini coefficient of bed distribution declined from 0.384 to 0.262 - although computed on ICU-type beds alone it remained 0.365 in fiscal year 2024 - and capacity growth (total +27.9%) was driven predominantly by HCU beds (+41.6%) while ICU beds grew only +8.0%. Conclusions: Japan's critical care supply structure is regionally rigid, with a stable set of approximately 140 SMAs lacking ICU beds for nearly a decade, yet road-network accessibility substantially mitigates the consequences of zone-level absence. Recent capacity growth - and much of the apparent equalization - has occurred predominantly in intermediate care. MeshScope-Region provides a standing, reproducible evidence base at the geographic unit of Japan's medical planning cycles.

Importance Pharmacogenomic (PGx) guidelines can improve medication efficacy and reduce toxicity, but their application in pediatric intensive care units (PICUs) remains largely unexplored. Objective To determine the frequency of medications with established PGx guidelines administered in the PICU and assess the capacity of exome sequencing to capture PGx phenotypes for these medications. Design Retrospective cohort study integrating electronic medical record and exome sequencing data. Setting Morgan Stanley Children's Hospital of NewYork-Presbyterian, a single center tertiary care children's hospital. Participants A total of 4,939 children admitted to the PICU (2020 - 2024), and 192 children admitted to the PICU who underwent exome sequencing for research purposes (2015 - 2023). Exposure Critical illness requiring PICU admission. Main Outcomes and Measures Frequencies of administration of medications with established PGx guidelines in the PICU and the proportion of individuals with exome sequencing with identifiable PGx phenotypes. Results Among 4,939 PICU patients, 37.2% (n=1,837) received at least one medication with established PGx guidelines and 14.4% (n=712) received two or more such medications. Twenty PGx genes were implicated; CYP2C9 was most common (17.3%, n=853). An estimated 8.2% of patients received medications for which PGx-guided recommendations would have altered clinical management. Among 192 patients who underwent exome sequencing, at least one metabolizer phenotype was identified in 62% (n=119). Conclusions and Relevance Many critically ill children receive medications with established PGx guidelines. This study highlights an opportunity for more personalized medicine for critically ill children admitted to a tertiary care hospital and assesses the strengths and weaknesses of exome sequencing to uncover pertinent PGx phenotypes.

Background: Female chronic pelvic pain disorders (CPPDs) are highly prevalent and frequently accompanied by sleep disturbance and autonomic nervous system (ANS) dysregulation. Heart rate variability (HRV), a non-invasive index of ANS function, may provide an objective, physiological correlate of sleep health and can be monitored using wearable devices, enabling a continuous, scalable approach. Objectives: This study examined whether wearable-derived daily HRV metrics are associated with self-reported sleep disturbance in women with CPPD(s) compared with healthy controls, using epoch-level data and generalized additive models. Methods: We conducted a retrospective observational study using up to 90 days of data from a mobile health research app. Participants were 128 women with CPPD(s) and 63 demographically matched healthy controls, who completed a daily PROMIS-based 3-item sleep disturbance questionnaire and wore Fitbit devices that provided 5-minute HRV epochs. Primary predictors were high frequency (HF) and low frequency (LF) power and root mean square of successive differences (RMSSD), with group (CPPD vs control), daily pain severity, and menstrual status as covariates. We fit separate generalized additive mixed models (GAMMs) for each HRV metric with a nonlinear smooth term and an HRV x Group interaction. Results: Higher HF and RMSSD were associated with lower sleep disturbance scores, and these associations were stronger in controls than in the CPPD group (HF x group B {approx} -1.59, p < 0.00010; RMSSD x group B {approx} -0.58, p < 0.0001). LF showed a more complex pattern but also differed by group (B {approx} -0.531, p < 0.0001). HRV smooth terms were highly nonlinear, and models explained ~8-9% of deviance in sleep disturbances. Pain severity and menstrual bleeding were strongly associated with worse sleep. Conclusion: These findings indicate small but consistent associations between wearable-derived HRV metrics and daily sleep disturbances in women with CPPD(s) and healthy controls, with weaker associations in CPPD(s). Integrating continuous HRV with symptom tracking could support low-burden and multimodal monitoring of sleep health in chronic pelvic pain, but prospective validation is needed before HRV can be used for diagnostic or treatment response decision making.

Background: International Classification of Diseases (ICD) codes are often used in epidemiological studies to track disease rates over time. Objective: This evaluation of ICD-code-based algorithms for electronic medical record (EMR) studies of Alzheimers disease (AD) and related dementias (ADRD) examines the impact of incorporating Centers for Medicare and Medicaid (CMS) data as an additional source of diagnostic and treatment information in Department of Veterans Affairs (VA) EMR studies. Methods: We performed a chart review of 100 VA Million Veteran Program (MVP) participants to evaluate algorithm performance. We also assessed genetic associations across algorithms in a large MVP cohort (n=396k). Results: Adding CMS data increased the number of detected cases, sensitivity, and positive predictive value, but decreased specificity and negative predictive value. Genetic analyses showed that broader (ADRD/dementia) algorithms with just VA data performed similarly to narrow (AD-focused) algorithms incorporating both VA and CMS ICD codes. Additionally, narrow AD algorithms based solely on VA data yielded the highest ORs, indicating the largest proportion of late-onset AD cases. Conclusions: We recommend using a broad (ADRD) algorithm without CMS or medication data, particularly for epidemiological studies or a strict AD algorithm including CMS and medication cases for genetic discovery of late-onset AD associations in VA EMR, and a strict AD algorithm without CMS data for applications focused solely on AD and sensitive to misspecification. Careful evaluation of algorithm performance is warranted in different EMR systems, as ICD coding practices vary by institution, as demonstrated by this comparison of VA EMR and CMS data.

Background: Urinary tract infection (UTI) is the most common secondary condition among people with spinal cord injury/disease (SCI/D). Intravesical Lacticaseibacillus rhamnosus GG (LGG) is an antibiotic-sparing approach to managing urinary symptoms. Objective: Determine the optimal number of doses of intravesical LGG for urinary symptom reduction. Design: Prospective, randomized, two-arm dosing trial. Setting: National recruitment with a local subsample providing urine samples in Washington, DC, USA. Participants: Adults with SCI/D and neurogenic lower urinary tract dysfunction (NLUTD) who use intermittent catheterization (IC); 177 enrolled and randomized (intention-to-treat), with 76 compliant instillers (39 low-dose, 37 high-dose) in the per-protocol analytic sample. Interventions: Two (2 doses/24 hours) or four (4 doses/36 hours) intravesical LGG regimens, self-initiated in response to cloudier or malodorous urine per the Self-Management Protocol using Probiotics (SMP-Pro). Main Outcome Measures: Primary: proportion achieving [&ge;]20% reduction on the Urinary Symptom Questionnaire for Neurogenic Bladder-Intermittent Catheter version (USQNB-IC). Secondary: urinary biomarkers (leukocyte esterase, nitrite, white blood cells, urinary neutrophil gelatinase-associated lipocalin [uNGAL]) and standard urine culture (SUC) in a local subsample. Results: By Day 2, 57.9% (63.8% low-dose; 51.2% high-dose) achieved [&ge;]20% total symptom reduction; high-dose success rose to 70.0% by Day 4. Thirty percent of high-dose participants did not respond at either time point and could not be distinguished from responders by demographics or urine biomarkers. Urinary biomarkers and SUC were unchanged pre- to post-instillation. No serious adverse events were adjudicated as attributable to intravesical LGG by an independent Data Safety Monitoring Board (DSMB). Conclusions: A two-dose course of intravesical LGG yields clinically meaningful symptom improvement in the majority of people with SCI/D and NLUTD who use IC; four doses benefits a meaningful subgroup of two-day non-responders, while a small cohort remains nonresponsive. These results provide preliminary dosing guidance and support progression to a definitive trial.

Background and Objectives: Stereoelectroencephalography (SEEG) involves the implantation of intracerebral electrodes to investigate drug-resistant epilepsy. SEEG requires millimetric accuracy to ensure safety and optimal mapping. Although studies have evaluated SEEG accuracy, there is substantial variability in reporting. Here we report on implantation accuracy in a large series using the most common accuracy metrics described in the literature and perform a detailed analysis of contributing factors. Methods: SEEG implantations between 2013 and 2025 were included. Application accuracy was computed for each implanted electrode. Specifically, Euclidean, radial, depth, and angle error were calculated at both target and entry points. Correlative and multivariable analyses were conducted between each variable and error metric. Trajectories were also grouped by atlas-derived lobar target. Results: No metrics met assumptions of normality and thus we report accuracy using median with interquartile range (IQR). In a series of 3176 trajectories, median Euclidean target and entry errors were lower for robot-assisted electrodes (n=2858) at 2.19 (IQR: 1.54-2.98) mm and 1.38 (IQR: 0.89-2.01) mm respectively, compared to frame-based (n=318, p<.001) at 2.76 (IQR:1.79-3.76) mm and 2.21 (IQR: 1.42-3.32) mm. Correlation and multivariable regression analysis showed target error was positively correlated with implantation angle, scalp thickness, skull thickness, and trajectory length. Target error was also higher in obese patients. On lobar analysis, parietal lobe trajectories were the most accurate and frontal lobe trajectories were the least accurate. On temporal lobe trajectory analysis, posterior hippocampus trajectories were the most accurate and temporal pole trajectories were the least accurate. Presence of mesial temporal sclerosis also impacted accuracy. Conclusions: We present a detailed description of SEEG implantation accuracy, demonstrating the superior accuracy and speed of robot-assisted to frame-based methods. Furthermore, we analyzed how accuracy varies with specific factors from a global to trajectory level, which can be accounted for when planning SEEG implantations.

Background. Patients on GLP-1 medications lose very different amounts of weight, and most published prediction models include only patients who complete six months. That design omits everyone who disengages earlier, which is the majority of the cohort. We built a tool that includes patients who disengage and delivers useful predictions at the week-8 visit, where the clinical decision is actually made. Methods. Beginning with 237,800 adults enrolled in a US telehealth GLP-1 program, we required a documented week-8 weight, a refill-confirmed dose, and reported ethnicity, yielding an analytic cohort of 22,538. We answered three questions: the patient's likely six-month weight loss and our confidence in it; the probability of dropout before six months; and when weight loss plateaus. For the first, we fit a cubic in week-8 percent loss plus 16 covariates, with quantile-regression bands at the 10th and 90th percentiles for the prediction interval, checking fractional-logit and isotonic recalibration as alternatives. For the second, we fit a logistic regression and compared it to gradient boosting. For the third, we fit a per-patient exponential trajectory among patients with at least four weight observations. We trained on enrollments before 2024-07-01 and tested on later ones, compared completer outcomes to published RCTs, and tested the week-8 anchor against measurements at weeks 2, 4, 6, 8, 10, 12, 16, and 20. Results. Mean six-month weight loss in completers was 11.7% on semaglutide and 14.1% on tirzepatide, in line with STEP-1 and SURMOUNT-1. Six-month disengagement was 66%. The prediction model reached test R2 = 0.65 with a mean absolute error of 2.76 percentage points. Calibration was strong: calibration-in-the-large was -0.52 pp and the calibration slope was 0.96. The 80% quantile-regression interval covered 76% of test patients; the 95% interval covered 93%. The disengagement model reached test AUC 0.79, against 0.74 for gradient boosting. Median plateau time among engaged patients was 387 days, longer in lower-BMI tertiles. The week-8 anchor gave R2 = 0.65, compared to 0.48 to 0.61 at earlier weeks and 0.67 to 0.91 at later weeks. We chose week 8 because 80% of slow responders reach their post-titration decision point at or before that visit. Two of twenty subgroup cells had reduced predictive accuracy; two more were too sparse to validate. Conclusions. Observed week-8 weight loss is the strongest predictor of six-month outcome. The model's accuracy (R2 = 0.65, MAE 2.76 pp) is appropriate for calibrating expectations and identifying patients for the post-titration decision, but not precise enough to drive that decision on its own. Disengagement is predictable at week 8 with AUC 0.79. Engaged patients plateau at a median of 387 days. Week 8 is the earliest visit at which titration is mostly complete, accuracy is in a useful range, and the post-titration decision remains actionable; later anchors predict better but inform a decision that has already been made for most patients. The model is temporally (internally) validated but not yet externally validated, and because it was developed on a single platform it should be regarded as a recalibration target rather than a drop-in deployment elsewhere. The tool is published as a public web calculator to support shared decision-making, though it is not precise enough on its own to drive an irreversible clinical decision. It is prognostic, not therapeutic; treatment-effect estimation is addressed in companion work.

Purpose: Pathogenic variants in NFIX cause Marshall-Smith syndrome and Malan syndrome (MALNS). We identified a severe subtype of MALNS characterized by adolescent-onset musculoskeletal deterioration and investigated functional consequences of underlying variants. Methods: Clinical data were collected from seven individuals with pathogenic NFIX variants. Wild-type and mutated recombinant NFIX DNA-binding domains (DBDs) were evaluated using biochemical, structural, and DNA-binding assays. Results: Six individuals carrying R116W, R116P, K125E, or G147E NFIX substitutions developed progressive muscle wasting, markedly reduced body mass index, and rapidly progressive scoliosis after the typical childhood features of MALNS; two died from disease-related complications. A seventh individual with R116G did not develop this severe phenotype. Functional studies on recombinant NFIX DBDs showed complete or near-complete loss of DNA-binding activity for R116W, R116P, K125E, and G147E despite preserved protein folding, consistent with disrupted DNA recognition and a potential dominant-negative mechanism. In contrast, R116G exhibited a 7.7{degrees}C decrease in thermal stability, which may support haploinsufficiency mediated by protein degradation. Conclusion: Specific NFIX missense variants define a severe subtype of MALNS associated with progressive musculoskeletal deterioration. In vitro functional studies support variant-specific disruption of DNA binding, providing a mechanistic basis of genotype-phenotype correlations and informing prognosis, clinical surveillance, and therapy development.

External validation of clinical AI emphasizes discrimination, although deployment requires the endpoint, probability estimates and operating policy to transport. Here we show that these layers diverged in retrospective bidirectional evaluation of five model families across eICU and MIMIC-IV. Coarse-label AUROC fell from 0.87-0.92 internally to 0.66-0.83 during source-only transfer. For assessment-conditioned repeated monitoring of persistence or recurrence, external AUROC reached 0.76-0.94, but removing assessment history reduced it by 0.16-0.32; broader features did not help consistently. Transported scores concentrated future-positive ICU stays 2.4-6.9-fold in the top risk decile. Development-selected cutoffs alerted 0.3-2.0% of prediction rows and captured 9.2-11.0% of future-positive rows; after deduplication, 4.9-12.2% of stays were alerted, capturing 43.9-49.4% of future-positive stays. Thus, ranking can persist while probability and policy transport remain site dependent. Layered validation is a prerequisite for prospective evaluation, not evidence of clinical benefit.

INTRODUCTION: The biomarker-based amyloid/ tau/ neurodegeneration (A/T/N) framework has become a popular staging method for Alzheimer's disease (AD) research. Previous studies use the framework either as a rule-based or data-driven approach but typically sacrifice either adaptivity or interpretability. METHODS: We present an interpretable, hybrid method, called Neurosymodal Data Fusion, for predicting incident AD in the ADNI dataset. Specifically, we encode the A/T/N framework as a logic program, where the input biomarker features are extracted by one or more neural networks. RESULTS: Our pipeline predicted four-year incident AD with a sensitivity of up to 0.84. Additionally, our models learned scores for each A/T/N profile, denoting relative importances to model predictions. These scores also indicated that empirically-derived cut-off values for the A and T criteria might be uninformative for the ADNI data. DISCUSSION: Our pipeline provides a novel way to use the A/T/N framework that could potentially improve early AD screening years before clinical manifestations.

Brain-computer interfaces (BCIs) have achieved impressive performance by decoding motor and articulatory signals associated with speech production. However, considerably less is known about whether higher-level semantic representations can be decoded from human cortical activity. Demonstrating semantic decoding would advance both our understanding of language organization and the development of BCIs that rely on conceptual rather than purely articulatory information. We recorded intracranial neural activity from patients undergoing stereotactic electroencephalography (sEEG) for clinical epilepsy monitoring while they performed language tasks requiring semantic processing. High-gamma power was extracted from local field potentials and used to generate trial-level features for supervised machine-learning classification. Classification performance was evaluated using cross-validation. Semantic category information was decoded significantly above chance, with mean classification accuracy reaching 29.8% across 15 semantic categories (chance = 6.7%). These findings demonstrate that high-gamma activity contains information about conceptual category membership that can be extracted on individual trials. These results provide evidence that semantic information is accessible from intracranial population recordings and support the feasibility of semantic decoding as a complementary direction for future language BCIs. Beyond neuroprosthetic applications, this work contributes to understanding how conceptual knowledge is represented in the distributed human language network.

Background: aneurysmal subarachnoid hemorrhage (aSAH) is neurological emergency associated with substantial mortality and disability. Current grading systems such as the modified Fisher Scale (mFS) and World Federation of Neurological Societies (WFNS) score, rely on semiquantitative and examination based assessments. Hence, they demonstrate limited predictive precision. The enhanced subarachnoid hemorrhage (eSAH) score is a simplified quantitative model integrating age, Glasgow Coma Scale (GCS), and cisternal subarachnoid hemorrhage volume (SAHV) to predict clinical outcomes after aSAH. Methods: We performed a retrospective multicenter cohort study that included 1088 patients across three tertiary-care centers the United States. Predictive performance for unfavorable functional outcome, in-hospital mortality and delayed cerebral ischemia (DCI) was evaluated using receiver operating characteristic (ROC) analysis and area under the curve (AUC). Comparative analyses were performed and compared to the WFNS and mFS grading systems. Results: the eSAH score demonstrated excellent discrimination for unfavorable functional outcome at discharge ( AUC 0.89 ) and in-hospital mortality (AUC 0.87). The DCI subscore demonstrated good discriminatory performance for predicting DCI (AUC 0.77). Compared with conventional grading systems, this was superior to both the WFNS (AUC 0.75) and the mFS ( AUC 0.70). increasing eSAH scores were additionally associated with progressively higher rates of mortality and unfavorable functional outcomes. Conclusion: the eSAH score demonstrates strong external validity, reproducibility and superior predictive performance compared with conventional grading systems in a large multicenter cohort. These findings support the clinical utility of quantitative hemorrhage burden integration for early risk stratification in patients with aSAH.

Intracranial neurophysiology studies have typically ignored signals from electrodes located in white matter (WM), assuming that their information content is artifactual or related to nearby gray matter (GM). Here, we tested the electrophysiological and functional features of signals recorded from different WM locations. Signals were recorded from 19 patients undergoing intracranial monitoring for drug-resistant epilepsy by means of stereo-electroencephalography (sEEG). Each sEEG electrode was classified into WM or GM based on the surrounding tissue. We obtained recordings from a total of 1,717 sEEG electrode contacts, 36% in WM, while the patients were in awake resting state (5 minutes). For each sEEG electrode, we employed a model-based spectral decomposition to separate periodic and aperiodic components, and we computed signal complexity metrics. For a subset of participants, we computed WM structural information from diffusion-weighted magnetic resonance imaging and we evaluated functional signals during a cognitive control task. Our results show that signals recorded from WM have different spectral features and higher complexity than GM. Complexity correlates positively with fractional anisotropy, and modulations related to behavior during the task were detected in WM. Overall, this indicates that WM signals carry information that may reflect signal propagation across WM fiber tracts.

Objective: Shunt-dependent hydrocephalus is a common and costly complication of aneurysmal subarachnoid hemorrhage (aSAH), affecting up to 28% of survivors. Existing prediction tools, including the Chronic Hydrocephalus Ensuing from SAH Score (CHESS), have limited discriminative accuracy. We developed the CHECKMATE score, a clinically practical tool to improve prediction of ventriculoperitoneal shunt dependency after aSAH. Methods: In this multicenter retrospective cohort of 486 patients with aSAH from Mayo Clinic (January 1, 2006-December 31, 2021), we used multivariable logistic regression and machine learning to identify independent predictors of ventriculoperitoneal shunt placement. The CHECKMATE score was derived from 5 weighted variables: symptomatic hydrocephalus (10 points), intraventricular hemorrhage (5 points), SAH volume greater than 10 mL (3 points), neutrophil-to-lymphocyte ratio greater than 12 (2 points), and 10-year incremental age thresholds starting at older than 60 years (1 point each). Results: Of 486 patients (mean age, 56.3 years; 64.6% female), 137 (28.2%) required ventriculoperitoneal shunt placement. The CHECKMATE score achieved an area under the curve of 0.808 (compared to 0.737 for CHESS), with a sensitivity of 0.85, specificity of 0.67, and negative predictive value of 0.92 at the optimal cutoff of 14 points. Conclusions: The CHECKMATE score outperforms CHESS for predicting ventriculoperitoneal shunt dependency after aSAH and is easily used at the bedside. Its high negative predictive value helps identify low-risk patients who may benefit from earlier external ventricular drain weaning and shorter hospital stays.

IMPORTANCE: Most United States children with neurodevelopmental disorders have not received genetic testing aligned with current guidelines. Integration of genetic counselors into non-genetics departments is a potential strategy to improve uptake, but prevalence and details of integrated care models are unknown. OBJECTIVE: To characterize availability, utilization, and perceived need for genetic counselors across non-genetics departments caring for patients with neurodevelopmental disorders DESIGN: Cross-sectional observational department-level survey SETTING: Child neurology, adult neurology, developmental pediatrics, child psychiatry, and adult psychiatry departments at Intellectual and Developmental Disabilities Research Centers PARTICIPANTS: The survey was distributed to 67 departments across 15 institutions. The departmental response rate was 52% (35/67), with at least one response from 87% (13/15) of institutions. EXPOSURE: Presence/absence of dedicated genetic counselor(s), where "dedicated" was defined as hired by the department MAIN OUTCOME(S) AND MEASURE(S): This was a descriptive study only, with no comparative statistical analyses due to the exploratory nature. RESULTS: One third of departments (34%; 12/35) reported having dedicated clinical genetic counselors. Prevalence was highest in child neurology (67%; 8/12), followed by adult neurology (40%; 2/5) and developmental pediatrics (22%; 2/9), with none in child psychiatry (0/7) or adult psychiatry (0/2). In almost all departments with genetic counselors (92%; 11/12), they directly billed for their services, which universally included pre-test counseling/consent and post-test counseling. In departments without genetic counselors, only 39% (9/23) reported providers ordered their own genetic testing. Among all departments, over half (57%) were interested in adding/increasing genetic counseling support, while 26% were unsure and 17% uninterested. Insufficient funding was the most cited barrier; only one department reported insufficient need. CONCLUSIONS AND RELEVANCE: Though currently implemented in only one third of departments, our findings suggest those with dedicated genetic counselors directly pursue genetic testing (without referring to genetics) more than those without genetic counselors. Interest in increasing or adding genetic counseling support was high, and though funding was a reported barrier, feasible funding models were described. In the context of limited medical geneticists and expanding precision therapies, alternate delivery models for neurodevelopmental genetic testing including genetic counselor integration in non-genetics departments may help to scale and sustain uptake.